Biohaven Ltd. (BHVN)Healthcare | Biotechnology | New Haven, United States | NYSE
11.42 USD
-0.39
(-3.302%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 10:58 a.m. EDT
Biohaven presents a stark dichotomy between its precarious financial reality and the aggressive speculative positioning surrounding it. Fundamentally, the company is in distress: it burns cash rapidly with negative free cash flow, carries debt exceeding its cash reserves, and reports a massive return on equity drag. The price action confirms this deterioration, having lost nearly 70% of its value in the trailing year despite a prior surge. This is not a value trap; it is a high-risk biotech play where the market is pricing in a binary outcome based on upcoming clinical data. The short-term outlook remains cautiously bearish due to the lack of a confirmed catalyst and the weight of the recent price decline, though the heavy call activity suggests smart money is preparing for a potential 'moonshot' scenario if trials succeed. However, without a definitive positive result, the downside risk is severe given the depleted runway. There is no dividend to provide a floor, making this a pure equity bet on future drug approvals. Investors should view this as a lottery ticket rather than an investment, suitable only for those willing to accept total loss in exchange for asymmetric upside potential. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.060455 |
| AutoARIMA | 0.060568 |
| AutoETS | 0.060981 |
| AutoTheta | 0.074372 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 2.53 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.759 |
| Excess Kurtosis | -0.22 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2430.331 |
| Market Cap | 1,724,919,936 |
| Forward P/E | -6.10 |
| Beta | 3.20 |
| Previous Name | Biohaven Research Ltd. |
| Website | https://www.biohaven.com |
As of Oct. 10, 2026, 10:58 a.m. EDT: Speculators are positioning aggressively for a massive upside move, evidenced by heavy call volume and open interest at strikes significantly above the current price (e.g., $30, $32.50, $65), alongside elevated implied volatility at these distant strikes. Conversely, put writers are accumulating significant protection at lower strikes ($7.50, $10.00), creating a 'long gamma' environment where the market expects a binary event—either a clinical trial success driving a parabolic rally or a failure triggering a crash to the downside. The skew suggests a speculative bet on a catalyst rather than a steady grind higher.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.3421659 |
| Address1 | 215 Church Street |
| All Time High | 62.21 |
| All Time Low | 5.415445 |
| Ask | 0.0 |
| Ask Size | 200 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 1,967,330 |
| Average Daily Volume3 Month | 2,624,087 |
| Average Volume | 2,624,087 |
| Average Volume10Days | 1,967,330 |
| Beta | 3.203 |
| Bid | 11.2 |
| Bid Size | 300 |
| Board Risk | 8 |
| Book Value | 0.081 |
| City | New Haven |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 11.42 |
| Current Ratio | 4.733 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 11.78 |
| Day Low | 11.165 |
| Debt To Equity | 2,430.331 |
| Display Name | Biohaven |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,794,254,400 |
| Earnings Timestamp Start | 1,794,254,400 |
| Ebitda | -520,109,088 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.373 |
| Enterprise Value | 1,754,088,960 |
| Eps Current Year | -1.64914 |
| Eps Forward | -1.87193 |
| Eps Trailing Twelve Months | -4.66 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 20 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 13.8484 |
| Fifty Day Average Change | -2.4284 |
| Fifty Day Average Change Percent | -0.175356 |
| Fifty Two Week Change Percent | -34.216587 |
| Fifty Two Week High | 18.566 |
| Fifty Two Week High Change | -7.146 |
| Fifty Two Week High Change Percent | -0.3848971 |
| Fifty Two Week Low | 7.48 |
| Fifty Two Week Low Change | 3.94 |
| Fifty Two Week Low Change Percent | 0.526738 |
| Fifty Two Week Range | 7.48 - 18.566 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,663,939,800,000 |
| Float Shares | 116,572,569 |
| Forward Eps | -1.87193 |
| Forward P E | -6.1006556 |
| Free Cashflow | -256,219,056 |
| Full Exchange Name | NYSE |
| Full Time Employees | 274 |
| Fullday Change | -0.71070004 |
| Fullday Change Percent | -6.0177817 |
| Fullday Price | 11.44 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.11205 |
| Held Percent Institutions | 0.95763 |
| Implied Shares Outstanding | 151,043,781 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. |
| Long Name | Biohaven Ltd. |
| Market | us_market |
| Market Cap | 1,724,919,936 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1796230042 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-14 |
| Net Income To Common | -586,841,024 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,064,768,486 |
| Number Of Analyst Opinions | 15 |
| Open | 11.79 |
| Operating Cashflow | -511,395,008 |
| Operating Margins | 0.0 |
| Overall Risk | 6 |
| Phone | 203 404 0410 |
| Pre Market Change | 0.019999504 |
| Pre Market Change Percent | 0.175127 |
| Pre Market Price | 11.44 |
| Pre Market Time | 1,791,982,381 |
| Prev Name | Biohaven Research Ltd. |
| Previous Close | 11.81 |
| Price Eps Current Year | -6.9248214 |
| Price Hint | 2 |
| Price To Book | 140.98766 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.275 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.82353 |
| Region | US |
| Regular Market Change | -0.39 |
| Regular Market Change Percent | -3.30229 |
| Regular Market Day High | 11.78 |
| Regular Market Day Low | 11.165 |
| Regular Market Day Range | 11.165 - 11.78 |
| Regular Market Open | 11.79 |
| Regular Market Previous Close | 11.81 |
| Regular Market Price | 11.42 |
| Regular Market Time | 1,791,921,602 |
| Regular Market Volume | 2,434,046 |
| Return On Assets | -0.71979 |
| Return On Equity | -7.99462 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 151,043,781 |
| Shares Percent Shares Out | 0.1261 |
| Shares Short | 19,053,695 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 19,000,171 |
| Short Name | Biohaven Ltd. |
| Short Percent Of Float | 0.16139999 |
| Short Ratio | 6.27 |
| Source Interval | 15 |
| State | CT |
| Symbol | BHVN |
| Target High Price | 42.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 21.26667 |
| Target Median Price | 20.0 |
| Total Cash | 267,866,000 |
| Total Cash Per Share | 1.773 |
| Total Debt | 297,035,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.66 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.0809 |
| Two Hundred Day Average Change | -0.6609001 |
| Two Hundred Day Average Change Percent | -0.054706197 |
| Type Disp | Equity |
| Volume | 2,434,046 |
| Website | https://www.biohaven.com |
| Zip | 6,510 |